Kailera Therapeutics Inc
KLRAHealthcare|Biotechnology|USA
$20.68
-0.33 (-1.57%)
About
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Stock Price
-20.5%(1Y)
Pipeline Summary
7 total trials2
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
Recruiting: 4Completed: 2ENROLLING_BY_INVITATION: 1
Active Trials (4)
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes
Phase 3Recruiting
Enrollment: 1,700 participants
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity
Phase 3Recruiting
Enrollment: 1,800 participants
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979Obesity
Phase 3Recruiting
Enrollment: 1,200 participants
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880Obesity
Phase 2Recruiting
Enrollment: 320 participants
BioScore
5.3/10
Watchlist
Ownership
Recent Insider Trades
Koppel AdamBUY
2026-04-201,562,500 shares @ $16
Bain Capital Life Sciences Investors, LLCBUY
2026-04-201,562,500 shares @ $16
Kaplan Andrew T.BUY
2026-04-208,398,438 shares @ $16
RTW INVESTMENTS, LPBUY
2026-04-20500,000 shares @ $16
BAIN CAPITAL INVESTORS LLCBUY
2026-04-208,398,438 shares @ $16
Recent News
2026-07-07 15:56:19
2026-07-07 13:51:17
Data last updated: Jul 13, 2026, 12:42 PM